+Compare
RVPH
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
107.36M

RVPH Reviva Pharmaceuticals Holdings Forecast, Technical & Fundamental Analysis

a blank check company, which focuses on the merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization, and exchangeable share transaction.

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for RVPH with price predictions
08:00 PM EDT Oct 02, 2023

RVPH in +7.45% Uptrend, rising for three consecutive days on September 28, 2023

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RVPH advanced for three days, in of 172 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 55 cases where RVPH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

RVPH moved above its 50-day moving average on September 11, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RVPH crossed bullishly above the 50-day moving average on September 14, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for RVPH moved out of overbought territory on September 15, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on September 25, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on RVPH as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RVPH turned negative on September 25, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RVPH broke above its upper Bollinger Band on September 14, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RVPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (66.225) is normal, around the industry mean (22.791). P/E Ratio (0.000) is within average values for comparable stocks, (131.379). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.084). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (309.467).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.17B. The market cap for tickers in the group ranges from 402 to 403.32B. NVO holds the highest valuation in this group at 403.32B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was 17%, and the average quarterly price growth was 21%. BNOX experienced the highest price growth at 337%, while RGMP experienced the biggest fall at -72%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was 139% and the average quarterly volume growth was 150%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

RVPH is expected to report earnings to fall 36.36% to -34 cents per share on November 13

Reviva Pharmaceuticals Holdings RVPH Stock Earnings Reports
Q3'23
Est.
$-0.35
Q2'23
Missed
by $0.27
Q1'23
Est.
$-0.30
Q4'22
Missed
by $0.16
Q3'22
Beat
by $0.11
The last earnings report on August 14 showed earnings per share of -55 cents, missing the estimate of -28 cents. With 168.22K shares outstanding, the current market capitalization sits at 107.36M.
A.I. Advisor
published General Information

General Information

a blank check company, which focuses on the merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization, and exchangeable share transaction.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
19925 Stevens Creek Boulevard
Phone
+1 408 501-8881
Employees
10
Web
https://www.revivapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSCNX13.01-0.15
-1.14%
Fidelity Advisor Asset Manager® 60% C
IVITX19.38-0.25
-1.27%
VY® Invesco Growth and Income S2
FGEAX19.55-0.27
-1.36%
Fidelity Advisor® Glbl Capital Apprec A
HNSGX11.54-0.17
-1.45%
Harbor Small Cap Growth Retirement
SVPSX69.52-1.47
-2.07%
ProFunds Small Cap Value Svc

RVPH and

Correlation & Price change

A.I.dvisor tells us that RVPH and IMUX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RVPH and IMUX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RVPH
1D Price
Change %
RVPH100%
+6.96%
IMUX - RVPH
28%
Poorly correlated
-5.67%
MGTX - RVPH
26%
Poorly correlated
-1.72%
IDYA - RVPH
26%
Poorly correlated
-1.20%
CDXC - RVPH
26%
Poorly correlated
-1.71%
WVE - RVPH
25%
Poorly correlated
-2.99%
More